Search

Chronic hand eczema (CHE) is a common inflammatory skin condition that significantly impacts the quality of life. From work-related disabilities to social embarrassment, pain, and financial costs, the burden on society is substantial. Managing this condition presents challenges such as long-term treatment, poor patient compliance, therapy side effects, and economic feasibility. As a result, significant efforts have been made in this field in recent years. Specifically, the broader understanding of CHE pathogenesis has led to the development of new drugs, both topical and systemic. The aim of this narrative review is to summarize the current available data on hand eczema pathophysiology and explore the resulting developments in drugs for its treatment. A comprehensive search on PubMed and the other main scientific databases was conducted using keywords related to CHE and its pathogenesis. The most relevant pathways targeted by therapies include the JAK-STAT cascade, IL-4, and IL-13 axis, phosphodiesterase 4 enzyme, and chemo-attractant cytokines. In the near future, physicians will have a plethora of therapeutic alternatives. Consequently, they should be well-trained not only in how to use these alternatives but also how to combine these treatments to address the ongoing challenges related to efficacy, tolerability, and safety. [ABSTRACT FROM AUTHOR]

Topical photodynamic therapy (PDT) is a non-invasive treatment modality frequently used in dermatology to treat superficial skin cancers but also some inflammatory or infectious dermatoses. PDT appears a more and more promising therapeutic option also for cutaneous lymphomas, either of T- or B-cell origin. It is a well-tolerated treatment and has excellent cosmetic outcomes, less side effects compared to other therapies (steroids, surgery, radiotherapy, and so on), no particular contraindications, and is easily repeatable in case of relapses. However, how PDT works in the treatment of cutaneous lymphoproliferative diseases is poorly understood and the literature data are still controversial. Further randomized, controlled clinical trials involving a greater number of patients and centers with a long follow-up are necessary to assess the efficacy of PDT and establish a unique standardized treatment protocol in relation to the lymphomatous disease and the type, thickness, and location of the lesions. [ABSTRACT FROM AUTHOR]

Alopecia areata (AA) is a common type of non-scarring alopecia of autoimmune origin. Management of alopecia areata in JAK-inhibitors era: are systemic and topical corticosteroids still useful? Several data in the literature have shown promising results of using JAK1 inhibitors for the treatment AA resistant to conventional therapy,[3] however, management of AA in JAK-inhibitors era may be difficult. [Extracted from the article]

A case report published in the International Journal of Dermatology discusses the potential use of topical tirbanibulin ointment 1% as a new treatment for recalcitrant plantar warts. The report highlights the challenges of treating plantar warts and the need for innovative approaches. Tirbanibulin, an inhibitor of tubulin polymerization, has shown promising results in inducing apoptosis in rapidly dividing cells infected by HPV. The case study describes the successful treatment of a large plantar wart with tirbanibulin cream, suggesting the need for further research to establish its efficacy and safety profile. [Extracted from the article]